The Preventative and Therapeutical Effect of Ursodeoxycholic Acid(UDCA) to Short Bowel Syndrome Patients

Jinling Hospital, China

Status and phase

Completed

Phase 4

Conditions

Short Bowel Syndrome

Treatments

Drug: ursodeoxycholic acid

Study type

Interventional

Funder types

Other

Identifiers

NCT01974336

UDCA-PNAC-SBS

Details and patient eligibility

About

The efficacy of UDCA in treating the parenteral nutrition-associated cholestasis(PNAC) has been identified by some studies in children without short bowel syndrome(SBS).Most of the adults who suffering PNAC have SBS. it limits the potential function of UDCA because of the lack of SBS patients and malabsorption of UDCA.Therefore, we design this clinical trial in our center of SBS to approach the preventative and therapeutical effect of UDCA to PNAC in adults with short bowel syndrome.

Enrollment

30 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with short bowel syndrome supported by total parenteral nutrition.
Patients have intestine more than 50cm.
Requirements of informed consent and assent of participant, parent or legal guardian as applicable
Consciousness and ability to cooperate.

Exclusion criteria

Patients have obstruction of biliary tract, infection, autoimmune disease, cancer
Patients have intestine less than 50cm
A clinically significant laboratory abnormality or a history of significant cardiac, pulmonary, hepatic, or renal disease
Female with positive pregnancy
Allergy to ursodeoxycholic acid